title: Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel.
abstract: We have previously established the efficacy of adenoviral gene delivery vectors for the treatment of bladder carcinoma in vivo. In the present work, we developed a gene therapy strategy for bladder cancer based on the replacement of the tumor suppressor p16, which is known to be mutated or deleted in a variety of human tumors, including those derived from the bladder. Previous reports have demonstrated that reconstitution of p16 has marked effects on the proliferative capacity of tumor cell lines both in vitro and in vivo, and that p16 expression causes resistance to some chemotherapeutic agents. In the present study, we describe the construction of the recombinant adenovirus Adp16, expressing the p16 gene, to evaluate the effects of transient p16 replacement in the context of bladder carcinoma. To identify candidate target cell lines, we screened a panel of bladder cancer cell lines for p16 and retinoblastoma (RB) protein expression. We demonstrate that Adp16 can mediate high-efficiency p16 replacement to the p16-negative cell lines EJ and UMUC-3. In addition, the reconstitution of p16 to the highly transducible p16-negative, RB-positive bladder cancer cell line EJ caused a profound inhibition of cell proliferation mediated by arrest in the G1 phase of the cell cycle. In contrast, the p16-positive, RB-negative cell line J82 was unaffected by this treatment. However, when adenovirally mediated p16 replacement was combined with the chemotherapeutics cisplatin and paclitaxel, a marked chemoresistance was observed in genetically corrected cells. This work has implications for future gene therapy strategies based on p16 replacement.
authors.affiliation: Department of Medicine, Section of Hematology/Oncology, Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota 55417, USA.
authors.forename: J
authors.initials: J
authors.lastname: Grim
authors.forename: A
authors.initials: A
authors.lastname: D'Amico
authors.forename: S
authors.initials: S
authors.lastname: Frizelle
authors.forename: J
authors.initials: J
authors.lastname: Zhou
authors.forename: R A
authors.initials: RA
authors.lastname: Kratzke
authors.forename: D T
authors.initials: DT
authors.lastname: Curiel
mesh_terms: D000256:Adenoviridae; D002289:Carcinoma, Non-Small-Cell Lung; D002453:Cell Cycle / Q000502:physiology*; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000633:toxicity*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000096:biosynthesis / Q000172:deficiency*; D019008:Drug Resistance, Neoplasm; D016193:G1 Phase; D016161:Genes, Retinoblastoma; D019942:Genes, p16; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D008175:Lung Neoplasms; D008654:Mesothelioma; D017239:Paclitaxel / Q000633:toxicity*; D011994:Recombinant Proteins / Q000096:biosynthesis; D016160:Retinoblastoma Protein / Q000096:biosynthesis; D014162:Transfection / Q000379:methods*; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000628:therapy
chemical_list: D019941:Cyclin-Dependent Kinase Inhibitor p16; D011994:Recombinant Proteins; D016160:Retinoblastoma Protein; D017239:Paclitaxel; D002945:Cisplatin